The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub‐analysis from the A1chieve® study. Issue 11 (6th October 2014)

• Record Type: Journal Article
• Authors: Hwang, Y.‐C.; Kang, J. G.; Ahn, K. J.; Cha, B. S.; Ihm, S.‐H.; Lee, S.; Kim, M.; Lee, B.‐W.
• Is Part Of: International journal of clinical practice. Volume 68:Issue 11(2014)
• Page Start: 1338
• Page End: 1344
• Publication Date: 2014-10-06
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.12482
• Languages: English
• ISSNs: 1368-5031

Abstract

Summary: Aims: In this study, we compared the glucose‐lowering effectiveness of insulin analogues and their combination according to baseline glycemic status in patients with type 2 diabetes (T2D) from the A1 chieve ® study conducted in Korea. Methods: This sub‐analysis from the A1 chieve ® study was a 24‐week prospective, multicenter, non‐interventional, open‐labelled study. Of the 4058 patients, 3074 patients who had their HbA1c level measured at baseline were included in this sub‐analysis. We classified patients into three groups according to baseline HbA1c levels: group I (HbA1c < 7.5%), group II (7.5% ≤ HbA1c < 9.0%) and group III (HbA1c ≥ 9.0%). Results: Patients in group I showed no significant HbA1c reduction with any insulin regimens (detemir, aspart, detemir and aspart or biphasic aspart 30 (Novo Nordisk A/S, DK‐2880 Bagsværd, Denmark) after 24 weeks of treatment. In group II, although HbA1c was decreased for all insulin regimens, there was no difference in mean HbA1c reduction among the four insulin regimens. In patients with a high baseline HbA1c level (group III), mean HbA1c reduction was the greatest in patients on a basal‐bolus regimen (detemir and aspart, −3.50%) and lowest in patients on a bolus regimen (aspart, −1.81%; p < 0.001). Conclusion: For optimal glycaemic control, a basal‐bolus regimen may be adequate for Korean patients with poorly controlled T2D (HbA1c ≥ 9.0%).